Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation

CpG Drives Human Transitional B Cells to Terminal Differentiation and Production of Natural Antibodies

(2014) F. Capolunghi et al.   JOURNAL OF IMMUNOLOGY

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

(2010) P. Perez-Galan et al.   BLOOD

BCL6, MUM1, and CD10 Expression in Mantle Cell Lymphoma

(2010) Gabriela Gualco et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

(2009) N. Di Bella et al.   BLOOD

How I treat mantle cell lymphoma

(2009) M. Ghielmini et al.   BLOOD

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition

(2009) G. Bianchi et al.   BLOOD

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

(2009) D. E. Reece et al.   BLOOD

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial

(2009) Owen A. O’Connor et al.   BRITISH JOURNAL OF HAEMATOLOGY

Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line

(2009) Shuqing Lü et al.   EXPERIMENTAL HEMATOLOGY

XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development

(2009) Derrick J. Todd et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells

(2009) T Rückrich et al.   LEUKEMIA

ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

(2009) Q. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Mantle cell lymphoma with flow cytometric evidence of clonal plasmacytic differentiation: A case report

(2008) Hina Naushad et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Dampening Ab responses using proteasome inhibitors followingin vivo B cell activation

(2008) Paolo Cascio et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Regulation of Immunoglobulin Light-Chain Recombination by the Transcription Factor IRF-4 and the Attenuation of Interleukin-7 Signaling

(2008) Kristen Johnson et al.   IMMUNITY

Point Mutation of the Proteasome  5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line

(2008) S. Lu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways

(2008) Edgar Gil Rizzatti et al.   LEUKEMIA & LYMPHOMA

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

(2008) David T Yang et al.   Molecular Cancer

Bortezomib-Resistant Nuclear Factor- B Activity in Multiple Myeloma Cells

(2008) S. Markovina et al.   MOLECULAR CANCER RESEARCH

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE

One step at a time: endoplasmic reticulum-associated degradation

(2008) Shruthi S. Vembar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

(2007) E. Hoster et al.   BLOOD